Eli Lilly Launches Foundayo — Weight Loss Pill Sparks Health Debate in Nigeria

Eli Lilly’s Foundayo™ (orforglipron) has been approved by the US Food and Drug Administration (FDA), marking a breakthrough in weight management with its unique formulation that allows users to take the GLP-1 pill anytime without dietary restrictions. The drug, developed by the US-based pharmaceutical giant, has drawn attention in Nigeria, where obesity rates have surged by 15% in the past five years, according to the Nigeria Centre for Disease Control (NCDC). The approval comes as the country grapples with rising non-communicable diseases, a growing public health challenge that aligns with broader African development goals of improving health outcomes and reducing chronic illness burdens.

Foundayo’s Approval Signals Shift in Global Weight Management

The FDA’s approval of Foundayo follows a rigorous evaluation process, with the drug showing a 12% average weight loss in clinical trials. Unlike other GLP-1 medications that require strict dosing with meals or water, Foundayo’s flexibility has been highlighted as a key advantage. The drug is expected to launch in the US in early 2025, with regulatory submissions already underway in several African countries, including Nigeria and Kenya. The National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria has confirmed it is reviewing the drug for potential approval, a move that could impact millions of Nigerians struggling with obesity.

Dr. Amina Hassan, a public health researcher at the University of Ibadan, said the approval of Foundayo is a significant step for weight management but warned of the need for careful regulation. “While the drug offers a new tool, it also raises concerns about accessibility, affordability, and long-term health effects,” she said. “Nigeria must ensure that such medications are not misused and are available to those who need them most, not just the wealthy.”

Obesity and Health Challenges in Africa

Obesity in Africa is on the rise, driven by urbanization, sedentary lifestyles, and the increasing availability of processed foods. In Nigeria alone, the prevalence of obesity has increased from 5.3% in 2010 to 11.4% in 2023, according to the World Health Organization (WHO). This trend is mirrored across the continent, where non-communicable diseases now account for 30% of all deaths, up from 15% in 2000. The approval of Foundayo underscores a growing global focus on addressing these health issues, but experts argue that the solution must go beyond medication.

Dr. Joseph Nwosu, a public health official with the African Union, stressed the need for a multi-pronged approach. “While drugs like Foundayo may help manage weight, they are not a substitute for healthy diets and active lifestyles,” he said. “Africa must invest in education, infrastructure, and policies that promote physical activity and access to nutritious food.”

Opportunities for African Healthcare Innovation

The global interest in GLP-1 drugs has also sparked discussions about the potential for African pharmaceutical companies to develop similar treatments. While Eli Lilly’s Foundayo is a US-based product, local firms are beginning to explore the space, with some receiving support from the African Development Bank (AfDB) to develop domestic solutions. The AfDB has allocated $500 million to support the growth of the African pharmaceutical sector, aiming to reduce dependence on foreign drugs and improve healthcare access.

VE, a leading African healthcare company, has expressed interest in partnering with international firms to bring similar weight management solutions to the continent. “We see an opportunity to innovate and provide affordable options for our patients,” said VE’s Chief Executive, Dr. Linda Mwangi. “However, this requires investment in research and regulatory frameworks that can support local production and distribution.”

Regulatory Hurdles and Public Health Concerns

Despite the potential benefits, regulatory bodies across Africa are cautious. The approval of new drugs often faces delays due to limited resources and complex approval processes. In Nigeria, NAFDAC has been working to streamline its procedures, but challenges remain. A recent report by the African Union found that only 30% of African countries have fully functional drug regulatory systems, which could slow the adoption of new treatments like Foundayo.

Public health advocates are also concerned about the potential for misuse. “We have seen similar cases where weight loss drugs were overprescribed or used inappropriately,” said Dr. Hassan. “It’s crucial that there is clear guidance on how these medications are prescribed and monitored.”

Looking Ahead: What to Watch

The next few months will be critical for the approval and potential rollout of Foundayo in Africa. NAFDAC is expected to release its decision on the drug by the end of 2024, while other countries like Kenya and Ghana are also in the review process. Meanwhile, the African Union is preparing a new health strategy that will focus on non-communicable diseases, including obesity, as a priority. The coming months will determine whether Foundayo becomes a tool for health improvement or a new challenge for African healthcare systems.